Skip to main content

Table 1 Demographic and clinicopathologic characteristics, and overall survival of patients with hepatoblastoma

From: Incidence trends and survival prediction of hepatoblastoma in children: a population-based study

Characteristic Patients [cases (%)] Deaths [cases (%)] Overall survival rate (%) P value
5-year 10-year
All patients 511 82 81.5 81.0  
Sex 0.139
 Male 320 (62.6) 58 (70.7) 79.3 78.4  
 Female 191 (37.4) 24 (29.3) 85.6 85.6  
Ethnicity 0.001
 Caucasian 392 (76.7) 55 (67.1) 83.9 83.9  
 African–American 44 (8.6) 15 (18.3) 58.4 58.4  
 Others 75 (14.7) 12 (14.6) 82.5 79.0  
Age at diagnosis 0.013
 0–1 323 (63.2) 41 (50.0) 85.8 85.8  
 2–4 152 (29.7) 36 (43.9) 72.9 71.0  
 5–18 36 (7.1) 5 (6.1) 79.9 79.9  
Year of diagnosis 0.108
 2004–2007 150 (29.4) 35 (42.7) 76.6 75.8  
 2008–2011 175 (34.2) 25 (30.5) 84.8 NR  
 2012–2015 186 (36.4) 22 (26.8) NR NR  
Tumor size < 0.001
 ≤ 5 cm 60 (11.7) 2 (2.4) 96.4 96.4  
 > 5 cm 400 (78.3) 62 (75.6) 82.2 81.5  
 Unknown 51 (10.0) 18 (22.0) 60.4 60.4  
Tumor stage < 0.001
 Local 231 (45.2) 17 (20.7) 91.0 91.0  
 Regional 157 (30.7) 27 (32.9) 80.4 80.4  
 Distant 109 (21.3) 34 (41.5) 65.7 65.7  
 Unstaged 14 (2.7) 4 (4.9) 77.4 64.5  
AFP status 0.028
 Negative 10 (2.0) 1 (1.2) 89.4 89.4  
 Positive 421 (82.4) 61 (74.4) 83.4 82.7  
 Unknown 80 (15.7) 20 (24.4) 70.9 70.9  
Surgery type < 0.001
 No surgery 86 (16.8) 46 (56.1) 43.2 39.4  
 Liver resection 341 (66.7) 29 (35.4) 89.3 89.3  
 Liver transplantation 84 (16.4) 7 (8.5) 90.1 90.1  
  1. NR not reached, AFP alpha-fetoprotein